Resistance to antiplatelet therapy

被引：44

作者：

Guthikonda S. ^{[1
]}

Lev E.I. ^{[1
]}

Kleiman N.S. ^{[1
]}

机构：

[1] Baylor College of Medicine, Houston, TX 77030

来源：

Current Cardiology Reports | 2005年 / 7卷 / 4期

关键词：

Aspirin; Clopidogrel; Arterioscler Thromb Vasc Biol; Aspirin Resistance; Indobufen;

D O I：

10.1007/s11886-005-0044-0

中图分类号：

学科分类号：

摘要：

Cardiovascular mortality continues to be high and events continue to occur in patients taking antiplatelet medications. Aspirin and clopidogrel have become integral parts of management in patients with coronary artery disease and after percutaneous angioplasty. However, the platelet responses to aspirin and clopidogrel are not uniform. Diminished or lack of response to these agents has been termed aspirin resistance and clopidogrel resistance. These phenomena have tremendous clinical significance as together they may occur in more than 50% of all patients on chronic therapy with aspirin or clopidogrel. Postulated mechanisms of aspirin and clopidogrel resistance include alterations in genetic, pharmacokinetic, and platelet properties. There is a dearth of information in regard to their clinical significance, methods to test them, and strategies to treat them. Further research is necessary in these areas to identify these patients and treat them appropriately. Copyright © 2005 by Current Science Inc.

引用

页码：242 / 248

页数：6

共 52 条

[31]

Rocca B., Secchiero P., Ciabattoni G., Et al., Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets, Proc. Natl. Acad. Sci. U. S. A., 99, pp. 7634-7639, (2002)

[32]

Kawasaki T., Ozeki Y., Igawa T., Kambayashi J., Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin, Stroke, 31, pp. 591-595, (2000)

[33]

Macchi L., Christiaens L., Brabant S., Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate, Thromb. Res., 107, pp. 45-49, (2002)

[34]

Valles J., Santos M.T., Aznar J., Et al., Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity, Circulation, 97, pp. 350-355, (1998)

[35]

Cipollone F., Ciabattoni G., Patrignani P., Et al., Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina, Circulation, 102, pp. 1007-1013, (2000)

[36]

Pratico D., Smyth E.M., Violi F., Et al., Local amplification of platelet function by 8-epi-prostaglandin F2a is not mediated by thromboxane receptor isoforms, J. Biol. Chem., 271, pp. 14916-14924, (1996)

[37]

Geiger J., Brich J., Honig-Liedl P., Et al., Specific impairment of human platelet P2Yac ADP receptor-mediated signaling by the antiplatelet drug clopidogrel, Arterioscler. Thromb. Vasc. Biol., 19, pp. 2007-2011, (1999)

[38]

Savi P., Pereillo J.M., Uzabiaga M.F., Et al., Identification and biological activity of the active metabolite of clopidogrel, Thromb. Haemost., 84, pp. 891-896, (2000)

[39]

Jaremo P., Lindahl T.L., Gransson S.B., Et al., Individual variations of platelet inhibition after loading doses of clopidogrel, J. Intern. Med., 252, pp. 233-238, (2002)

[40]

Gurbel P.A., Bliden K.P., Hiatt B.L., Et al., Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, pp. 2908-2913, (2003)

← 1 2 3 4 5 6 →